↓ Skip to main content

Dove Medical Press

Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study

Overview of attention for article published in Clinical and Experimental Gastroenterology, January 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
51 Mendeley
Title
Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study
Published in
Clinical and Experimental Gastroenterology, January 2018
DOI 10.2147/ceg.s143913
Pubmed ID
Authors

Carsten Bantel, Shiva S Tripathi, David Molony, Tony Heffernan, Susmita Oomman, Vivek Mehta, Sara Dickerson

Abstract

Opioids are an effective treatment for moderate-to-severe pain. However, they are associated with a number of gastrointestinal side effects, most commonly constipation. Laxatives do not target the underlying mechanism of opioid-induced constipation (OIC), so many patients do not have their symptoms resolved. Fixed-dose prolonged-release (PR) oxycodone/naloxone (OXN) tablets contain the opioid agonist oxycodone and the opioid antagonist naloxone. Nal-oxone blocks the action of oxycodone in the gut without compromising its analgesic effects. To evaluate the effectiveness of PR OXN in patients with severe pain who had laxative-refractory OIC with their previous opioid. The study was carried out in 13 centers across the UK and Ireland, using a bespoke online tool to capture patients' data. Patients were reviewed according to normal clinical practice of each center and rated any changes in their constipation and quality of life (QoL) since starting PR OXN. Any change in patients' laxative use was also recorded. One hundred and seven patients were entered into the database, and 81 went on to attend at least one review. Of these, 54 (66.7%) reported an improvement in constipation and 50 (61.7%) reported an improvement in QoL since starting PR OXN. Fifty-seven patients (70.4%) said they had reduced laxative intake; 48 (59.3%) only needed laxatives as required. PR OXN reduced symptoms of constipation, improved QoL and reduced laxative intake in patients with OIC. It has a potential place early in any treatment strategy for severe pain in patients using opioids, particularly in patients who may be predisposed to constipation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 18%
Student > Master 7 14%
Other 6 12%
Student > Bachelor 5 10%
Student > Doctoral Student 4 8%
Other 8 16%
Unknown 12 24%
Readers by discipline Count As %
Medicine and Dentistry 18 35%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Nursing and Health Professions 4 8%
Agricultural and Biological Sciences 3 6%
Social Sciences 3 6%
Other 3 6%
Unknown 15 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2018.
All research outputs
#17,114,587
of 25,932,719 outputs
Outputs from Clinical and Experimental Gastroenterology
#189
of 335 outputs
Outputs of similar age
#274,602
of 453,620 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#6
of 8 outputs
Altmetric has tracked 25,932,719 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 335 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,620 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.